ITPRIPL1

Summary

ITPRIPL1 (ITPRIP like 1, HGNC:29371) is a protein-coding gene on chromosome 2q11.2, encoding Inositol 1,4,5-trisphosphate receptor-interacting protein-like 1 (Q6GPH6). Functions as a ligand of CD3E, inhibiting TCR-CD3 complex signaling to regulate T cell activation.

Enables receptor ligand activity. Involved in negative regulation of T cell receptor signaling pathway. Located in membrane. Is active in plasma membrane.

Source: NCBI Gene 150771 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 97 total
• MANE Select transcript: NM_001008949

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29371
Approved symbol	ITPRIPL1
Name	ITPRIP like 1
Location	2q11.2
Locus type	gene with protein product
Status	Approved
Aliases	D1B
Ensembl gene	ENSG00000198885
Ensembl biotype	protein_coding
OMIM	620821
Entrez	150771

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000361124, ENST00000420176, ENST00000420728, ENST00000439118, ENST00000536814, ENST00000888305, ENST00000939004

RefSeq mRNA: 5 — MANE Select: NM_001008949 NM_001008949, NM_001163523, NM_001163524, NM_001324490, NM_178495

CCDS: CCDS33250, CCDS46360, CCDS54378

Canonical transcript exons

ENST00000439118 — 3 exons

Exon	Start	End
ENSE00001617323	96325747	96325849
ENSE00001661635	96326642	96328353
ENSE00001708147	96325317	96325565

Expression profiles

Bgee: expression breadth ubiquitous, 165 present calls, max score 89.15.

FANTOM5 (CAGE): breadth broad, TPM avg 0.9309 / max 24.4714, expressed in 483 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
21455	0.9239	482
21456	0.0070	3

Top tissues by expression

253 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	89.15	gold quality
left testis	UBERON:0004533	85.13	gold quality
right testis	UBERON:0004534	84.90	gold quality
tibialis anterior	UBERON:0001385	84.46	silver quality
granulocyte	CL:0000094	84.12	gold quality
testis	UBERON:0000473	81.87	gold quality
ventricular zone	UBERON:0003053	78.40	gold quality
ileal mucosa	UBERON:0000331	78.04	gold quality
pancreatic ductal cell	CL:0002079	77.52	silver quality
ganglionic eminence	UBERON:0004023	76.09	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	74.46	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	74.31	gold quality
upper arm skin	UBERON:0004263	71.65	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	71.34	gold quality
vermiform appendix	UBERON:0001154	69.99	gold quality
bone marrow cell	CL:0002092	69.36	silver quality
stromal cell of endometrium	CL:0002255	69.35	gold quality
lymph node	UBERON:0000029	68.58	gold quality
omental fat pad	UBERON:0010414	68.42	gold quality
peritoneum	UBERON:0002358	68.34	gold quality
cortical plate	UBERON:0005343	68.24	gold quality
adipose tissue of abdominal region	UBERON:0007808	66.90	gold quality
cerebellar cortex	UBERON:0002129	66.39	gold quality
cerebellar hemisphere	UBERON:0002245	66.37	gold quality
minor salivary gland	UBERON:0001830	66.12	gold quality
deltoid	UBERON:0001476	65.62	silver quality
right hemisphere of cerebellum	UBERON:0014890	65.34	gold quality
gall bladder	UBERON:0002110	65.22	gold quality
apex of heart	UBERON:0002098	65.20	gold quality
cerebellum	UBERON:0002037	64.76	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.59

Regulation

Is transcription factor: no

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Itpripl1	ENSMUSG00000074825
rattus_norvegicus	Itpripl1	ENSRNOG00000012151

Paralogs (9): ITPRIP (ENSG00000148841), CGAS (ENSG00000164430), MAB21L4 (ENSG00000172478), MAB21L3 (ENSG00000173212), MB21D2 (ENSG00000180611), MAB21L1 (ENSG00000180660), TMEM102 (ENSG00000181284), MAB21L2 (ENSG00000181541), ITPRIPL2 (ENSG00000205730)

Protein

Protein identifiers

Inositol 1,4,5-trisphosphate receptor-interacting protein-like 1 — Q6GPH6 (reviewed: Q6GPH6)

All UniProt accessions (3): Q6GPH6, C9JNT4, H7C0T2

UniProt curated annotations — full annotation on UniProt →

Function. Functions as a ligand of CD3E, inhibiting TCR-CD3 complex signaling to regulate T cell activation. Induces stable CD3E-NCK1 binding, thereby preventing the CD3E-ZAP70 interaction and subsequently inhibiting the activation of the downstream ERK-NFkB signaling cascade and calcium influx.

Subcellular location. Cell membrane.

Tissue specificity. Expressed in testis and tumoral cells.

Similarity. Belongs to the ITPRIP family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q6GPH6-1	1	yes
Q6GPH6-2	2
Q6GPH6-3	3

RefSeq proteins (5): NP_001008949, NP_001156995, NP_001156996, NP_001311419, NP_848590 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR024810	MAB21L/cGLR	Family
IPR026250	ITPRIP-like	Family
IPR046906	Mab-21_HhH/H2TH-like	Domain

Pfam: PF20266

UniProt features (11 total): sequence variant 3, topological domain 2, splice variant 2, signal peptide 1, chain 1, transmembrane region 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6GPH6-F1	78.60	0.49

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 87 (showing top): GOBP_REGULATION_OF_T_CELL_RECEPTOR_SIGNALING_PATHWAY, GOBP_REGULATION_OF_ANTIGEN_RECEPTOR_MEDIATED_SIGNALING_PATHWAY, GOBP_ANTIGEN_RECEPTOR_MEDIATED_SIGNALING_PATHWAY, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_NEGATIVE_REGULATION_OF_T_CELL_RECEPTOR_SIGNALING_PATHWAY, GOBP_REGULATION_OF_IMMUNE_RESPONSE, YGACNNYACAR_UNKNOWN, GOBP_CALCIUM_ION_IMPORT, TGCTGAY_UNKNOWN, GOBP_T_CELL_RECEPTOR_SIGNALING_PATHWAY, PU1_Q6, GOBP_NEGATIVE_REGULATION_OF_ANTIGEN_RECEPTOR_MEDIATED_SIGNALING_PATHWAY, GOMF_SIGNALING_RECEPTOR_BINDING, RGAGGAARY_PU1_Q6, YNGTTNNNATT_UNKNOWN

GO Biological Process (8): T cell differentiation (GO:0030217), negative regulation of T cell receptor signaling pathway (GO:0050860), calcium ion import (GO:0070509), signal transduction (GO:0007165), negative regulation of signal transduction (GO:0009968), T cell activation (GO:0042110), positive regulation of MAPK cascade (GO:0043410), T cell receptor signaling pathway (GO:0050852)

GO Molecular Function (2): receptor ligand activity (GO:0048018), protein binding (GO:0005515)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
signal transduction	2
lymphocyte differentiation	1
T cell activation	1
T cell receptor signaling pathway	1
regulation of T cell receptor signaling pathway	1
negative regulation of antigen receptor-mediated signaling pathway	1
calcium ion transport	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
regulation of signal transduction	1
negative regulation of cell communication	1
negative regulation of signaling	1
negative regulation of response to stimulus	1
lymphocyte activation	1
MAPK cascade	1
regulation of MAPK cascade	1
positive regulation of intracellular signal transduction	1
antigen receptor-mediated signaling pathway	1
signaling receptor binding	1
signaling receptor activator activity	1
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

932 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ITPRIPL1	FAHD2B	Q6P2I3	608
ITPRIPL1	FAM178B	Q8IXR5	593
ITPRIPL1	WDR54	Q9H977	549
ITPRIPL1	ANKRD39	Q53RE8	509
ITPRIPL1	TMEM102	Q8N9M5	486
ITPRIPL1	ANKRD36	A6QL64	450
ITPRIPL1	CIAO1	O76071	447
ITPRIPL1	CNNM3	Q8NE01	446
ITPRIPL1	SLC75A1	Q14728	437
ITPRIPL1	TMX4	Q9H1E5	421
ITPRIPL1	MB21D2	Q8IYB1	417
ITPRIPL1	FER1L5	A0AVI2	416
ITPRIPL1	ANKRD36C	Q5JPF3	403
ITPRIPL1	STARD7	Q9NQZ5	399
ITPRIPL1	CCDC181	Q5TID7	393

IntAct

39 interactions, top by confidence:

A	B	Type	Score
VAPB	FAM83G	psi-mi:“MI:0914”(association)	0.730
ADCY9	NEMP1	psi-mi:“MI:0914”(association)	0.640
STK4	STRN	psi-mi:“MI:0914”(association)	0.610
ITPRIPL1	SGTA	psi-mi:“MI:0915”(physical association)	0.560
UBQLN1	ITPRIPL1	psi-mi:“MI:0915”(physical association)	0.560
SGTA	ITPRIPL1	psi-mi:“MI:0915”(physical association)	0.560
ITPRIPL1	UBQLN1	psi-mi:“MI:0915”(physical association)	0.560
GPR21	TMEM120B	psi-mi:“MI:0914”(association)	0.530
HTR2C	KLRG2	psi-mi:“MI:0914”(association)	0.530
SPINT2	UPK3BL1	psi-mi:“MI:0914”(association)	0.530
CD226	MEN1	psi-mi:“MI:0914”(association)	0.530
GPR183	NRP1	psi-mi:“MI:0914”(association)	0.530
CHRM3	PLD2	psi-mi:“MI:0914”(association)	0.530
TSPYL1	GPC3	psi-mi:“MI:0914”(association)	0.530
CD63	LGALS8	psi-mi:“MI:0914”(association)	0.530
GPR183	GPC1	psi-mi:“MI:0914”(association)	0.530
RASSF1	MAP1B	psi-mi:“MI:0914”(association)	0.530
CANX	HLA-A	psi-mi:“MI:0914”(association)	0.350
RTN4	ESYT2	psi-mi:“MI:0914”(association)	0.350
VAPA	ESYT2	psi-mi:“MI:0914”(association)	0.350
HCST	TMEM120B	psi-mi:“MI:0914”(association)	0.350
HIDE1	TMEM120B	psi-mi:“MI:0914”(association)	0.350
CHST7	POTEF	psi-mi:“MI:0914”(association)	0.350
ABCA2	ABCD4	psi-mi:“MI:0914”(association)	0.350
POPDC1	DCX	psi-mi:“MI:0914”(association)	0.350
P2RX1	FAM20B	psi-mi:“MI:0914”(association)	0.350
GRAMD1B	ADD2	psi-mi:“MI:0914”(association)	0.350

BioGRID (51): ITPRIPL1 (Two-hybrid), ITPRIPL1 (Two-hybrid), ITPRIPL1 (Affinity Capture-MS), ITPRIPL1 (Affinity Capture-MS), ITPRIPL1 (Affinity Capture-MS), SGTA (Two-hybrid), ITPRIPL1 (Affinity Capture-MS), ITPRIPL1 (Affinity Capture-MS), ITPRIPL1 (Affinity Capture-MS), ITPRIPL1 (Affinity Capture-MS), ITPRIPL1 (Two-hybrid), ITPRIPL1 (Two-hybrid), ITPRIPL1 (Two-hybrid), ITPRIPL1 (Two-hybrid), CDSN (Two-hybrid)

ESM2 similar proteins: A2ASA8, A2CI98, A2CJ06, A4IG61, A4IIW0, A7MB64, A8E4S7, O15482, P59025, P79621, Q08AI8, Q0IES7, Q0IES8, Q0V9X7, Q29H55, Q29H56, Q3TNL8, Q3UJB3, Q3UPR7, Q567X9, Q569B5, Q5MYT7, Q5QGT7, Q5TW90, Q640Z9, Q66H52, Q6DCQ5, Q6GNM3, Q6GPH6, Q6GQ81, Q6GQD9, Q6NYB4, Q7QHX4, Q80VA5, Q80ZF2, Q80ZI2, Q8BPP1, Q8C8C1, Q8CEZ4, Q8CI17

Diamond homologs: A2ASA8, A7MB64, Q3TNL8, Q66H52, Q6GPH6, Q8IWB1, Q90XY5, Q567X9

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
ITPRIPL1	up-regulates	ITPR1	binding
PLCG1	up-regulates	ITPRIPL1

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 59 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Class A/1 (Rhodopsin-like receptors)	6	11.1×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
G protein-coupled receptor signaling pathway	9	5.9×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

97 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	89
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

287 predictions. Top by Δscore:

Variant	Effect	Δscore
2:96325562:GACG:G	donor_gain	1.0000
2:96326640:A:AG	acceptor_gain	1.0000
2:96326641:G:GG	acceptor_gain	1.0000
2:96326641:GAT:G	acceptor_gain	1.0000
2:96325561:TGACG:T	donor_gain	0.9900
2:96325562:GACGG:G	donor_gain	0.9900
2:96325563:ACG:A	donor_gain	0.9900
2:96325566:G:GG	donor_gain	0.9900
2:96325568:GAGT:G	donor_loss	0.9900
2:96325569:AGTA:A	donor_loss	0.9900
2:96326632:A:AG	acceptor_gain	0.9900
2:96326640:AGAT:A	acceptor_gain	0.9900
2:96326641:GA:G	acceptor_gain	0.9900
2:96326641:GATG:G	acceptor_gain	0.9900
2:96325564:CG:C	donor_gain	0.9800
2:96325565:GG:G	donor_gain	0.9800
2:96326633:C:G	acceptor_gain	0.9800
2:96326641:GATGC:G	acceptor_gain	0.9800
2:96327004:G:GC	acceptor_gain	0.9800
2:96325563:ACGGT:A	donor_gain	0.9600
2:96325564:CGGT:C	donor_gain	0.9600
2:96325565:GGTG:G	donor_gain	0.9600
2:96325566:G:GA	donor_gain	0.9600
2:96325567:T:G	donor_gain	0.9600
2:96325568:GA:G	donor_gain	0.9600
2:96325569:AGTAA:A	donor_gain	0.9600
2:96325570:G:T	donor_gain	0.9600
2:96326714:T:TA	acceptor_gain	0.9600
2:96326883:G:GG	donor_gain	0.9400
2:96326643:TGCAG:T	acceptor_gain	0.9300

AlphaMissense

3668 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:96328024:T:A	W465R	0.993
2:96328024:T:C	W465R	0.993
2:96327221:T:C	L197P	0.991
2:96327981:A:C	K450N	0.991
2:96327981:A:T	K450N	0.991
2:96327811:T:A	W394R	0.990
2:96327811:T:C	W394R	0.990
2:96327980:A:T	K450I	0.990
2:96328026:G:C	W465C	0.990
2:96328026:G:T	W465C	0.990
2:96328052:T:C	L474P	0.990
2:96328118:G:T	G496V	0.990
2:96327895:T:C	C422R	0.989
2:96328182:T:A	N517K	0.989
2:96328182:T:G	N517K	0.989
2:96328225:G:C	A532P	0.989
2:96327845:T:C	F405S	0.988
2:96326986:T:C	C119R	0.987
2:96327298:T:C	F223L	0.987
2:96327300:T:A	F223L	0.987
2:96327300:T:G	F223L	0.987
2:96327998:T:C	L456P	0.987
2:96328187:T:C	F519S	0.987
2:96327989:T:C	L453P	0.986
2:96327813:G:C	W394C	0.985
2:96327813:G:T	W394C	0.985
2:96328049:G:C	R473P	0.985
2:96328085:T:A	L485H	0.985
2:96328118:G:A	G496D	0.985
2:96328108:T:C	F493L	0.983

dbSNP variants (sampled 300 via entrez): RS1000718882 (2:96330971 A>T), RS1001012022 (2:96324039 T>C), RS1001843075 (2:96330261 A>C), RS1001937513 (2:96330510 C>A,T), RS1003612343 (2:96328586 A>T), RS1004195974 (2:96329448 C>T), RS1004977746 (2:96327589 C>G), RS1004999119 (2:96330307 T>A,C), RS1005098002 (2:96327826 G>C,T), RS1005372734 (2:96329972 C>G,T), RS1005669964 (2:96324621 C>T), RS1006027702 (2:96324460 G>T), RS1006058706 (2:96324900 G>T), RS1006366914 (2:96326447 T>C), RS1007303634 (2:96325338 C>A,T)

Disease associations

OMIM: gene MIM:620821 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST005231_1	Major depressive disorder	4.000000e-06

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

19 total (human), top 19 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
GSK-J4	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
zinc chromate	increases abundance, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	increases abundance, decreases expression	1
perfluorooctane sulfonic acid	increases expression	1
entinostat	increases expression	1
Leflunomide	decreases expression	1
Benzo(a)pyrene	increases expression	1
Demecolcine	decreases expression	1
Formaldehyde	decreases expression	1
Oxygen	decreases expression	1
Quercetin	increases expression	1
Thimerosal	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	decreases expression	1
Urethane	decreases expression	1
Vincristine	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer